Genomics

For patients with inoperable brain tumors, new diagnostic guidelines offer hope by validating CSF profiling, a disruptive technology poised to redefine care.

Bionano Genomics brings back OGM pioneer Dr. Alex Hastie as CSO. It's a strategic move to accelerate clinical adoption and restore investor confidence.

Illumina's appointment of Eli Lilly's R&D chief isn't just a new hire; it's a strategic masterstroke signaling a deeper push into drug development.

uniQure's early trial data for AMT-260 shows promise in reducing severe seizures, but experts urge cautious optimism on the long road to a cure.

For decades, insomnia treatment meant risky sedatives. Now, a new class of drugs is revolutionizing sleep science, promising safer rest for millions.

Kardium’s landmark FDA win and a new wave of innovators signal a biotech boom, cementing British Columbia's status as a global hub for health innovation.

A new study of 100M insurance claims reveals a shocking failure: nearly 9 in 10 women in some states get no osteoporosis care after a fracture. Why?

For years, CIDP patients faced limited options. Now, a wave of targeted therapies promises to transform treatment, sparking a multi-billion dollar market boom.

With Hillary Aiken leading its new philanthropic arm, 23andMe Research Institute bets on private giving to accelerate its 'public good' DNA revolution.

A new drug from Cambrian Bio shows promise in activating a key metabolic switch. This could lead to treatments that burn fat while preserving muscle mass.

A Taipei delegation at BIO 2026 signals Taiwan's strategic pivot from manufacturing to R&D, seeking global partners for its late-stage drugs and platforms.

At BIO 2026, Transpire Bio isn't just presenting; it's pitching a new paradigm for medicine, using inhalation to tackle everything from diabetes to cancer.

GSK and Spero Therapeutics have won FDA approval for Utebzi, the first oral carbapenem for complex UTIs, a move that could slash healthcare costs.

Chronic fatigue, anxiety, and burnout are surging. A new wave of data-driven, integrative medicine claims to have the answer, moving beyond symptoms to the root cause.

A landmark grant and trial expansion signal a pivotal shift in Parkinson's research, blending genetic targeting, global collaboration, and digital health.

Azitra is betting its future on a radical pivot, leveraging its science for cosmetics and biotech tools. Is this a savvy move for faster cash or a risky dilution of focus?

New data on ersodetug reveals a calculated strategy to conquer hyperinsulinism, balancing patient hope with the harsh realities of the biotech market.

A new collaboration aims to weaponize the immune system against tough GI cancers. We break down the science, strategy, and nearly $800M per program deal.

A new alliance between Sun Life and Medzown moves beyond financial safety nets, using AI to steer patients to clinical trials and reshape corporate healthcare.

As a rare Ebola strain rages in a DRC warzone, the G7 pledges massive aid. But with fragile peace deals and no proven cure, is it enough to stop a global crisis?